Diagnostic molecular assays are conducted for any new COVID-19 symptom. Test results, exposure investigation details, vaccination status, and employee demographics are included in the OHS record. All actively employed HCP with a positive molecular assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are contacted by Occupational Health Services (OHS) for systematic index case interview and contact tracing as described elsewhere. The Mayo Clinic consists of main campuses in Minnesota, Florida, and Arizona, and a healthcare system spanning southern Minnesota and western Wisconsin, employing approximately 76 000 HCP. We aim to provide an estimate of vaccine effectiveness (VE) in the subpopulation of HCP reached through employer vaccination programs, to enrich the rapidly growing body of evidence in this area. By mid-December, 2 messenger RNA (mRNA) vaccines had received emergency use authorization (EUA) by the US Food and Drug Administration (FDA), both of which demonstrated approximately 95% efficacy against symptomatic COVID-19 in clinical trials. In early December 2020, the Centers for Disease Control and Prevention recommended that HCP be the first occupational group prioritized to receive newly authorized COVID-19 vaccines in the United States (US).

Healthcare personnel (HCP) are among the highest-risk workers for coronavirus disease 2019 (COVID-19). COVID-19, SARS-CoV-2, vaccine effectiveness, healthcare personnel, mRNA

Cid episode 1343